The pathogenesis of persistent non-erosive reflux disease treated with proton-pump inhibitors as measured with the Symptom Index

[1]  C. Yi,et al.  Relevance of ineffective esophageal motility to secondary peristalsis in patients with gastroesophageal reflux disease , 2014, Journal of gastroenterology and hepatology.

[2]  L. Frazzoni,et al.  Esophageal chemical clearance is impaired in gastro‐esophageal reflux disease – a 24‐h impedance‐pH monitoring assessment , 2013, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[3]  M. Mellow,et al.  The effect of baclofen on nocturnal gastroesophageal reflux and measures of sleep quality: a randomized, cross‐over trial , 2012, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[4]  M. Fox,et al.  Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography 1 , 2012, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[5]  E. Savarino,et al.  Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients , 2012, Journal of Gastroenterology.

[6]  M. Hongo,et al.  Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs—TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan , 2011, Journal of Gastroenterology.

[7]  R. Conigliaro,et al.  Weakly acidic refluxes have a major role in the pathogenesis of proton pump inhibitor‐resistant reflux oesophagitis , 2010, Alimentary pharmacology & therapeutics.

[8]  K. Blondeau.  Treatment of gastro‐esophageal reflux disease: the new kids to block , 2010, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[9]  D. Sifrim,et al.  The Role of Weakly Acidic Reflux in Proton Pump Inhibitor Failure, Has Dust Settled? , 2010, Journal of neurogastroenterology and motility.

[10]  Yuriko Tanaka,et al.  Characteristics of Symptomatic Reflux Episodes in Patients with Non-Erosive Reflux Disease Who Have a Positive Symptom Index on Proton Pump Inhibitor Therapy , 2010, Digestion.

[11]  R. Hunt,et al.  Diagnosis and Management of Non-Erosive Reflux Disease – The Vevey NERD Consensus Group , 2009, Digestion.

[12]  Y. Fujiwara,et al.  Epidemiology and clinical characteristics of GERD in the Japanese population , 2009, Journal of Gastroenterology.

[13]  K. Blondeau,et al.  Regional oesophageal sensitivity to acid and weakly acidic reflux in patients with non‐erosive reflux disease , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[14]  E. Savarino,et al.  The Role of Nonacid Reflux in NERD: Lessons Learned From Impedance-pH Monitoring in 150 Patients off Therapy , 2008, The American Journal of Gastroenterology.

[15]  J. Tack,et al.  Oesophageal tone and sensation in the transition zone between proximal striated and distal smooth muscle oesophagus , 2008, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[16]  T. Hucl,et al.  Non-erosive and erosive gastroesophageal reflux diseases: No difference with regard to reflux pattern and motility abnormalities , 2008, Scandinavian journal of gastroenterology.

[17]  S. Roman,et al.  Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors , 2007, Gut.

[18]  V. Wong,et al.  Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  R. Mittal,et al.  Review article: acidity and volume of the refluxate in the genesis of gastro‐oesophageal reflux disease symptoms , 2007, Alimentary pharmacology & therapeutics.

[20]  R. Fass.  Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. , 2007, Journal of clinical gastroenterology.

[21]  Y. Bhat,et al.  Capsaicin receptor (TRPV1) and non-erosive reflux disease , 2006, European journal of gastroenterology & hepatology.

[22]  I. Wiklund,et al.  Assessing Symptoms in Gastroesophageal Reflux Disease: How Well Do Clinicians' Assessments Agree with Those of Their Patients? , 2005, The American Journal of Gastroenterology.

[23]  J. Peters,et al.  Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology , 2004, Journal of Gastrointestinal Surgery.

[24]  B. Dean,et al.  Effectiveness of proton pump inhibitors in nonerosive reflux disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  J. Dent,et al.  Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux , 2004, Gut.

[26]  Y. Kinoshita,et al.  Symptom relief in patients with reflux esophagitis: Comparative study of omeprazole, lansoprazole, and rabeprazole , 2003, Journal of gastroenterology and hepatology.

[27]  L. Marzio,et al.  Effect of acute and chronic administration of the GABAB agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease , 2003, Gut.

[28]  R. Fass.  Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease , 2003, American Journal of Gastroenterology.

[29]  J. Dent,et al.  Control of transient lower oesophageal sphincter relaxations and reflux by the GABAB agonist baclofen in patients with gastro-oesophageal reflux disease , 2002, Gut.

[30]  D. Castell,et al.  Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. , 2001, Gastroenterology.

[31]  J. Dent,et al.  Motor function of the proximal stomach and visceral perception in gastro-oesophageal reflux disease , 1998, Gut.

[32]  P. Kahrilas.  Gastroesophageal reflux disease. , 1996, JAMA.

[33]  B. Weusten,et al.  The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. , 1994, Gastroenterology.

[34]  P. Kasapidis,et al.  Differences in manometry and 24-H ambulatory pH-metry between patients with and without endoscopic or histological esophagitis in gastroesophageal reflux disease. , 1993, The American journal of gastroenterology.

[35]  R. Goyal,et al.  Characteristics of vagal esophageal tension-sensitive afferent fibers in the opossum. , 1989, Journal of neurophysiology.

[36]  W. Wu,et al.  The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring. , 1988, The American journal of gastroenterology.

[37]  K. DeVault.  Laparoscopic Antireflux Surgery vs Esomeprazole Treatment for Chronic GERD: The LOTUS Randomized Clinical Trial , 2011 .

[38]  L. Marzio,et al.  Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. , 2003, Gut.

[39]  E. Quigley,et al.  Gastro-oesophageal reflux disease-spectrum or continuum?. , 1997, QJM : monthly journal of the Association of Physicians.

[40]  M. Médici,et al.  A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. , 1989, Current medical research and opinion.